Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: LaurietCecília Monteiro, William Alvin McElveen, Seema Datta et al.|Neurology|2023Cited by 104
Primate cerebrospinal fluid CHI3L1 reflects brain TREM2 agonismStephen Schauer, Anne Biever, Chang Hoon Cho et al.|Alzheimer s & Dementia|2024Cited by 5